Gemcitabine after Pancreatic Cancer Surgery Improves Survival

Patients who received the chemotherapy drug gemcitabine after surgery for pancreatic cancer lived 2 months longer than patients who had surgery alone, according to the final results of a large, randomized clinical trial presented at the ASCO annual meeting last week. Read the rest of this entry »